View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 1, 2022

Sanofi Phase III tolebrutinib trials placed on partial hold by US FDA

The move comes after some cases of drug-induced liver injury were detected with tolebrutinib exposure in Phase III trials.

Sanofi’s Phase III clinical trials of tolebrutinib for multiple sclerosis (MS) and myasthenia gravis have been placed on partial clinical hold by the US Food and Drug Administration (FDA).

With the latest development, new participant enrolment in the US has been halted while the study drug will be suspended for subjects who are part of the trial for less than 60 days. 

Furthermore, US subjects who have concluded a minimum of 60 days in the study will continue to receive the treatment.

The partial clinical hold comes after a small number of drug-induced liver injury cases were detected with tolebrutinib exposure in Phase III studies. 

Most of the affected subjects were observed to have concurrent complications that are found historically to predispose to drug-induced liver injury. 

Notably, the rise in laboratory values used for tracking liver injury was found to be reversible following discontinuation of the treatment in all cases. 

After holding talks with the FDA about these cases, trial protocols were updated in May 2022 to revise the frequency of monitoring and subject enrolment criteria were modified to eliminate pre-existing risk factors for hepatic dysfunction.

Subject enrolment in the clinical programme is progressing with the updated trial protocols and improved safety monitoring in regions outside the US. 

To assess the effectiveness of safety measures, the company is also working with independent data monitoring committee members and investigators globally. 

The programme in MS has been enrolling subjects since 2019 and comprises over 2000 patients presently receiving tolebrutinib for treatment durations of up to three years.

An investigational brain-penetrant and bioactive Bruton’s tyrosine kinase (BTK) inhibitor, tolebrutinib attains cerebrospinal fluid (CSF) concentrations required for acting on B lymphocytes and microglial cells. 

Currently, tolebrutinib is being analysed in Phase III clinical trials to treat relapsing forms of MS (RMS), non-relapsing secondary progressive MS (nrSPMS), primary progressive MS (PPMS) and myasthenia gravis (MG).

The safety and efficacy of the therapy have so far not been assessed by any regulatory agency globally.

In June this year, Sanofi and GSK reported positive data from the trial of their adjuvanted bivalent D614 and Beta (B.1.351) Covid-19 vaccine candidate.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena